Sexual dysfunction in patients with allergic rhinoconjunctivitis

Kırmaz, Cengiz; Aydemi̇r, Ömer; Bayrak, Papatya; Yüksel, Hasan; Ozenturk, Ozlem; Degirmenci, Sedat

doi:10.1016/s1081-1206(10)61013-7

Cited by 50 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is associated with impairments in how patients function in day-to-day life (1053). It has been known for a long time that having an allergic reaction causes significant fatigue and mood changes (1054), some impairment of cognitive function (1055,1056), depression and anxiety (1057,1058).…”

Section: Social Lifementioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

Section: Social Lifementioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,859

1,761

View full text Add to dashboard Cite

Section: Abstract: 5-grass-pollen Tablet • Allergic Rhinitis • Allergmentioning

confidence: 99%

“…The physical symptoms of AR can cause sleep disturbances, leading to daytime fatigue and somnolence, decreased cognitive functioning, absenteeism from school and work and impaired performance at school and work [11]. AR may also affect mood and social functioning [11] and can even contribute to sexual dysfunction in adults [12]. Moreover, in children, AR is often comorbid with chronic middle-ear effusions, sinusitis, adenoidal and tonsillar hypertrophy and acute and serious otitis media [9].…”

mentioning

confidence: 99%

Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience

Didier

Wahn

Horak

et al. 2014

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

OralairÒ (OA) (Stallergenes, Antony, France) is a unique pre-and co-seasonal 5-grass-pollen sublingual immunotherapy tablet launched in 2008, and now approved in 31 countries worldwide for the treatment of grass-pollen allergic rhinitis and rhinoconjunctivitis. OA is the first oral treatment with a consistent, well-balanced allergen extract that mimics natural exposure and sensitization. A wealth of data exists from over 5 years of clinical and realworld experience demonstrating the efficacy and safety of OA for grass-pollen-allergy treatment. OA is highly effective from the first pollen season in all patient subgroups, including children and those with comorbid mild asthma, irrespective of sensitization status and symptom severity. OA also has sustained long-term benefits for symptom control and quality of life. This article provides an overview of the pharmacodynamics and pharmacology of OA; its efficacy, safety, tolerability and cost-effectiveness for the treatment of allergic rhinitis and rhinoconjunctivitis and its role in clinical practice. Allergic rhinitis (AR) is a common chronic inflammatory illness, characterized by rhinorrhea, nasal congestion, sneezing, nasal and ocular pruritis and watery eyes [1]. Inhalation of allergens by sensitized individuals triggers the IgE-mediated release of inflammatory mediators and cytokines, leading to a rapid appearance of symptoms [2]. AR has historically been classified as 'seasonal' or 'perennial' depending on whether symptoms occur with seasonal exposure to aeroallergens or are present throughout the year. Seasonal AR is most commonly attributed to plant pollen and other outdoor allergens, while perennial AR is associated with indoor allergens, such as dust mites, mold, cockroaches and pet dander, although it can also be associated with pollen in areas where this is prevalent year-round [3,4].In 2001, the WHO-sponsored Allergic Rhinitis and its Impact on Asthma meeting produced guidelines proposing an alternative classification of the condition into 'intermittent' or 'persistent' AR, and grading symptoms as 'mild' or 'moderate/severe' [5]. Globally, the prevalence of seasonal ('hay fever') and perennial AR ranges from 7 to 42 and 1 to 13%, respectively, with the former being more common in children than adults [6]. The length of exposure to seasonal allergens is dependent on geographic location and climatic conditions [4]; in Europe, the main pollen season typically occurs from March to July, with slight variations according to latitude [7].Approximately 500 million people worldwide [6], including an estimated 30-60 million in the USA [4] 1309Drug Profile suffer from AR, and its prevalence is increasing in most countries [2]. It is estimated that from 10 to 30% of adults and up to 40% of the pediatric population have AR [3,9]. While AR does not directly lead to mortality, it places a considerable burden on affected individuals, who often have a reduced quality of life (QoL), compared with non-sufferers [10]. The physical symptoms of AR can cause sleep disturbance...

show abstract

“…Patients with AR had significantly worse sexual function than the non-AR patients [8]. Another study conducted with allergic rhinoconjuctivitis(ARC) patients showed that quality of sexual life in patients with ARC in both men and women were poorer than controls [9]. The effects of vertigo, hearing loss, halitosis and obstructive sleep apnea (OSAS) on sexual health have been previously investigated.…”

Section: Discussionmentioning

confidence: 99%